➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Harvard Business School
Colorcon
Johnson and Johnson
Baxter

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

Patent: 9,364,567

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,364,567
Title:Fragments of p97 and uses thereof
Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising the p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
Inventor(s): Vitalis; Timothy Z. (Vancouver, CA), Gabathuler; Reinhard (Montreal, CA)
Assignee: biOasis Technologies, Inc. (Richmond, CA)
Application Number:14/210,029
Patent Claims:see list of patent claims

Details for Patent 9,364,567

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial biOasis Technologies, Inc. (Richmond, CA) 2033-03-13 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial biOasis Technologies, Inc. (Richmond, CA) 2033-03-13 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial biOasis Technologies, Inc. (Richmond, CA) 2033-03-13 RX Orphan search
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin VIAL;SINGLE-DOSE 761060 001 2018-04-09   Start Trial biOasis Technologies, Inc. (Richmond, CA) 2033-03-13 RX Orphan search
Glaxosmithkline Llc BENLYSTA belimumab INJECTABLE;INJECTION 761043 001 2017-07-20   Start Trial biOasis Technologies, Inc. (Richmond, CA) 2033-03-13 RX search
Wyeth Pharms Inc BESPONSA inotuzumab ozogamicin POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER 761040 001 2017-08-17   Start Trial biOasis Technologies, Inc. (Richmond, CA) 2033-03-13 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,364,567

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2014160438   Start Trial
United States of America 10772939   Start Trial
United States of America 2014322132   Start Trial
United States of America 2016324937   Start Trial
United States of America 2019008929   Start Trial
United States of America 9993530   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Boehringer Ingelheim
Express Scripts
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.